Influenza is one of the most studied viruses on Earth, yet it remains remarkably effective at infecting people year after year. That persistence comes down to how the virus is built, how it hijacks your cells, and how it outmaneuvers your immune system. The influenza A virus carries its genetic material on eight separate RNA segments, a design quirk that gives it an unusual ability to evolve and reshuffle its genes. Understanding how it moves from the surface of a cell all the way to the nucleus, copies itself, and slips past immune defenses explains not only why flu keeps coming back but also why it is so difficult to develop a universal vaccine.
Anatomy of the Virus Particle
An influenza virion is roughly spherical (though filamentous forms also exist) and is wrapped in a lipid envelope stolen from the host cell it last budded out of. Studding that envelope are two main surface proteins: hemagglutinin (HA) and neuraminidase (NA). HA is the protein the virus uses to latch onto cells, and NA is the enzyme that frees newly made viruses so they can spread. The two have to work in careful balance; if HA binds too tightly and NA cuts too weakly, new virions get stuck on the cell surface, and if the reverse is true, the virus cannot attach in the first place.1PubMed Central. Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics A smaller but critically important protein called M2 sits in the envelope and acts as a proton channel, letting hydrogen ions flow into the virus interior at the right moment during infection.
Beneath the envelope lies a shell of matrix protein (M1), which gives the particle structural rigidity. Inside that shell are the eight RNA segments, each wrapped by many copies of a protein called nucleoprotein (NP) and capped at one end by a three-part polymerase complex made of the subunits PA, PB1, and PB2. Each segment plus its proteins forms a ribonucleoprotein complex (RNP), and these RNPs are the functional units the virus needs for copying its genome once it reaches the host cell nucleus.2PubMed Central. Influenza A virus-generated small RNAs regulate the switch from transcription to replication Having eight separate segments instead of one continuous genome is unusual among viruses and carries enormous evolutionary consequences discussed later in this article.
Latching On and Getting Inside
Entry begins when HA on the virus surface recognizes sialic acid, a sugar molecule that decorates many proteins and lipids on the surface of your cells. The specific type of linkage between sialic acid and its neighboring sugar matters enormously. Human influenza strains prefer a particular linkage arrangement abundant in the human upper airway, while avian influenza strains prefer a different arrangement found mainly in bird intestinal cells.3PubMed Central. Sialic acid tissue distribution and influenza virus tropism This receptor preference is one of the main reasons bird flu viruses do not easily infect humans. But the picture is more complex than just two linkage types: the length of the sugar chain, chemical modifications along it, and even sulfur-containing additions all influence how well a given flu strain can grab hold.4PubMed Central. Influence of Host Sialic Acid Receptors Structure on the Host Specificity of Influenza Viruses
Once HA binds sialic acid, the cell engulfs the virus in a bubble of membrane called an endosome. The endosome’s interior gradually becomes more acidic as the cell pumps protons into it. When the pH drops to around 5.0–5.5, HA undergoes a dramatic shape change: a hidden stretch of amino acids called the fusion peptide shoots outward and inserts into the endosomal membrane.5PubMed. Membrane fusion mechanisms: the influenza hemagglutinin paradigm and its implications for intracellular fusion Cryo-electron microscopy has captured intermediate structures during this process, including a long triple-helical coil that may act as a bridge between the viral and endosomal membranes, pulling them together until they fuse.6Nature. Structural transitions in influenza haemagglutinin at membrane fusion pH At a finer level, lowering the pH from about 7.8 to 5.2 first releases fusion peptides from their resting pockets and then triggers an unwinding of the central helices of HA into an extended form, a rearrangement that provides the mechanical force to merge the two membranes.7PLOS Pathogens. Structural intermediates in the low pH-induced transition of influenza hemagglutinin
Uncoating and Freeing the Genome
Membrane fusion alone does not finish the job. The viral RNPs are still bundled together and wrapped in M1 matrix protein. They need to be released into the cell’s cytoplasm as individual segments so they can travel to the nucleus. This is where the M2 proton channel earns its keep. While the virus sits in the early endosome, M2 lets protons seep through the viral envelope and acidify the virus interior.8PubMed Central. Influenza M2 proton channels The internal M1 protein shell dissolves at a pH of roughly 5.5 to 6.0, loosening its grip on the RNPs.9PubMed Central. Model of influenza virus acidification
This is a two-step process, and both steps are essential. If you skip the early-endosomal acidification stage or block M2 with a drug, the genome does not release properly and infection stalls.10PubMed Central. pH-Controlled two-step uncoating of influenza virus The older antiviral drugs amantadine and rimantadine worked exactly this way, plugging the M2 channel. Unfortunately, widespread resistance has made them largely useless against circulating strains today.
Getting Into the Nucleus
Unlike many RNA viruses that replicate in the cytoplasm, influenza needs to get its RNPs into the cell nucleus. This is unusual and creates extra hurdles for the virus, but it also gives influenza access to the host’s own gene-copying machinery in a way that turns out to be extremely useful during transcription.
After M1 dissolves and the RNP bundles are freed, a transport protein called transportin 1 recognizes a specific signal on residual M1 still clinging to the RNPs. Transportin 1 strips off the remaining M1, which allows the RNP bundles to separate into individual segments.11Nature Microbiology. Influenza virus uses transportin 1 for vRNP debundling during cell entry Once separated, each RNP is recognized by a different set of import proteins (importin-α and importin-β), which ferry them through nuclear pores. The nucleoprotein coating each RNP carries two distinct nuclear import signals, and both contribute to getting the job done, though one appears to be the primary driver.12PubMed Central. Nuclear import of influenza A viral ribonucleoprotein complexes is mediated by two nuclear localization sequences on viral nucleoprotein The virus essentially uses two different members of the import machinery family for two distinct steps: one for stripping the coat and one for nuclear entry.
Cap-Snatching and Genome Copying
Once inside the nucleus, the viral polymerase does something no other RNA virus polymerase is known to do in quite the same way. It physically associates with the host cell’s own RNA polymerase II (the enzyme that copies the cell’s genes) and steals the beginnings of the cell’s freshly made messenger RNA transcripts. Specifically, the PB2 subunit of the viral polymerase grabs the protective “cap” structure on a host transcript, while the PA subunit acts as an endonuclease, cutting the host RNA roughly 10 to 13 nucleotides downstream.13Nature. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit The resulting short capped fragment then serves as a primer, giving the polymerase a running start to transcribe viral messenger RNA from the viral RNA template.14Nature. Mechanism of co-transcriptional cap snatching by influenza polymerase This trick, called cap-snatching, is how the virus disguises its mRNAs as the cell’s own, letting them be recognized and translated by the cell’s protein-making machinery.
Cap-snatching handles transcription, the making of messenger RNA for protein production. But the virus also needs to copy its full-length genome for packaging into new virions, and that process (replication) is different: it produces complete RNA copies without a stolen cap. The balance between these two activities shifts over the course of infection. Early on, when host capped mRNAs are plentiful, the polymerase favors transcription. As infection progresses and polymerase concentrations rise, the system tilts toward genome replication.15PubMed Central. Regulation of influenza RNA polymerase activity and the switch between replication and transcription by the concentrations of the vRNA 5′ end, the cap source, and the polymerase Small viral RNA fragments generated during replication may also help trigger this switch, accumulating as a signal that it is time to start making more genomes rather than more protein instructions.2PubMed Central. Influenza A virus-generated small RNAs regulate the switch from transcription to replication
Exiting the Nucleus and Budding Out
Newly copied RNPs must leave the nucleus and reach the cell surface for assembly into new virions. This export depends on a complex involving the viral nuclear export protein (NEP), M1, and the host cell’s own export machinery. NEP recruits M1 to the RNPs inside the nucleus, forming an export-competent complex.16PubMed Central. The nuclear export protein of H5N1 influenza A viruses recruits Matrix 1 (M1) protein to the viral ribonucleoprotein to mediate nuclear export M1 itself carries a nuclear export signal; when that signal is mutated, M1 gets trapped in the nucleus, and with it, the RNPs — virus production drops sharply.17PubMed Central. A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication
At the cell’s surface, newly made HA, NA, and M2 are already embedded in the plasma membrane, clustered in cholesterol-rich patches called lipid rafts. Spherical virions bud from these rafts in a process that does not require the cell’s actin skeleton, while filamentous virions — long, thread-like particles that some strains produce — do depend on actin filaments for their formation.18PubMed. A functional link between the actin cytoskeleton and lipid rafts during budding of filamentous influenza virions The final step is release. Freshly budded virions are still tethered to the cell by sialic acid residues on the cell surface that HA would happily re-bind. NA cuts those sialic acid tethers, freeing the new virions to spread to neighboring cells and clearing a path through the sialic-acid-rich mucus lining the airway.19PubMed Central. Investigation of the binding and cleavage characteristics of N1 neuraminidases from avian, seasonal, and pandemic influenza viruses using saturation transfer difference nuclear magnetic resonance Oseltamivir (Tamiflu) and zanamivir (Relenza) work by blocking NA, leaving virions stuck and unable to spread.
Shutting Down the Alarm
Your cells are not defenseless. When an infection is detected, cells normally produce type I interferons — signaling proteins that warn neighboring cells to prepare antiviral defenses. Influenza counters this with a protein called NS1, encoded on the smallest of its eight genome segments. NS1 is a potent interferon antagonist: it blocks the production of type I interferon in both airway cells and immune cells called dendritic cells, buying the virus critical time to replicate before the immune system ramps up.20PubMed Central. The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells
NS1 does this partly by targeting a cellular sensor called RIG-I, which normally detects viral RNA and triggers the interferon alarm. Specifically, NS1 interferes with two host enzymes (TRIM25 and Riplet) that activate RIG-I, preventing the sensor from sounding the alarm. Interestingly, this interference is species-specific: the NS1 proteins from different flu strains vary in how well they suppress RIG-I in human versus avian cells, which has implications for cross-species transmission.21PLOS Pathogens. Species-Specific Inhibition of RIG-I Ubiquitination and IFN Induction by the Influenza A Virus NS1 Protein
Drift, Shift, and Why Flu Keeps Coming Back
Influenza evolves through two broad mechanisms. The first, antigenic drift, is the slow accumulation of mutations as the virus replicates. The viral polymerase lacks a proofreading function, so copying errors are frequent. Some of those errors land in the antigenic sites on HA — the very spots your antibodies recognize. Over time, enough mutations accumulate that antibodies from a past infection or vaccination no longer bind well, and you become susceptible again. Some of these HA mutations alter receptor binding at the same time they change the virus’s appearance to the immune system, meaning that antigenic diversification can happen even without direct antibody pressure, as compensatory mutations in other parts of HA restore receptor binding.22PubMed Central. Compensatory hemagglutinin mutations alter antigenic properties of influenza viruses
The second mechanism, antigenic shift, is far more abrupt and is the reason pandemics happen. Because the genome is split across eight segments, when two different influenza A viruses infect the same cell, their segments can mix and match during replication — a process called reassortment.23PubMed. Constraints, Drivers, and Implications of Influenza A Virus Reassortment If a pig cell, for example, is simultaneously infected by a human strain and an avian strain, the new viruses emerging from that cell could carry HA from the bird virus on a backbone adapted to humans. The result is a virus that the human population has never encountered, and immune protection built up over years of seasonal flu exposure may offer little help. This reassortment-driven shift has been the engine behind every flu pandemic of the last century.24PubMed Central. Implications of segment mismatch for influenza A virus evolution
Why Bird Flu Rarely Crosses Into Humans
Beyond receptor preference, there is a deeper molecular barrier to cross-species infection. Avian influenza polymerases work poorly in human cells, and a host protein called ANP32A is the reason. The avian version of ANP32A has an extra 33 amino acids that the human version lacks, and avian flu polymerases depend on that extra stretch to replicate efficiently. In human cells, the shorter ANP32A does not support avian polymerase activity well.25Nature. Species difference in ANP32A underlies influenza A virus polymerase host restriction For avian flu to replicate in people, the polymerase typically needs to acquire adaptive mutations — the best known is a single amino acid change in PB2 — that compensate for the shorter human ANP32A.
Pigs are a concern in pandemic planning partly because their version of ANP32A supports a broader range of influenza polymerases than the human version does, binding the polymerase more tightly and allowing both avian and mammalian viruses to replicate.26PubMed Central. Swine ANP32A Supports Avian Influenza Virus Polymerase This makes pigs an ideal mixing vessel where avian and human strains can co-infect and reassort, potentially generating viruses with pandemic potential.
Original Antigenic Sin and Immune Memory
Your immune system’s memory of past flu strains is generally a good thing, but it comes with a quirk that complicates vaccination. When you encounter a new flu strain, your immune system preferentially boosts antibodies against the strain it first met in childhood, even if those antibodies are a poor match for the current threat. This phenomenon, called original antigenic sin, means your antibody response to a novel strain is partly hijacked by old memories.27PubMed Central. From Original Antigenic Sin to the Universal Influenza Virus Vaccine The practical consequence is that people exposed to a new flu variant can produce antibodies skewed toward older strains at the expense of making antibodies against the novel parts of the new virus, potentially worsening the current infection.28The Journal of Immunology. Original Antigenic Sin Responses to Influenza Viruses
This is one reason universal flu vaccine design is so challenging. A vaccine targeting the conserved stem region of HA — the part that changes less from year to year — is one leading approach. Antibodies that bind this stem can neutralize a broad range of flu strains and subtypes.29PubMed Central. Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin Nanoparticle-based vaccines designed to present the stem in a way that activates the right precursor immune cells are in development for both major groups of influenza A.30PubMed Central. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages However, the virus can still acquire mutations in the stem and in NA that reduce the effectiveness of even broadly neutralizing stem antibodies, so the arms race continues.31PubMed Central. Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody
Defective Particles That Fight the Virus
Not every virion the cell produces is functional. During replication, the polymerase sometimes produces shortened, defective copies of genome segments. Virions carrying these truncated genomes are called defective interfering particles (DIPs). They cannot replicate on their own, but they compete with normal viruses for the cell’s replication machinery, effectively slowing down production of fully functional virus.32PubMed Central. Defective Interfering Particles of Influenza Virus and Their Characteristics, Impacts, and Use in Vaccines and Antiviral Strategies: A Systematic Review Cells infected with high concentrations of DIPs show stronger interferon responses and higher rates of programmed cell death, and a significant fraction of those cells produce no functional viral proteins at all.33PubMed. Impact of defective interfering particles on virus replication and antiviral host response in cell culture-based influenza vaccine production
DIPs are more than a curiosity. Researchers are exploring them as a potential therapeutic strategy: administering synthetic DIPs to an infected airway could, in theory, outcompete the real virus and dampen infection. They also matter in vaccine manufacturing, where accumulation of DIPs during egg- or cell-based flu virus production can reduce the yield of usable vaccine virus.
How Researchers Manipulate Flu in the Lab
Much of what we know about each step in the flu lifecycle comes from a technique called reverse genetics. Instead of isolating a virus from nature and studying it as-is, researchers build it from scratch using DNA copies of all eight genome segments cloned into plasmids. Transfecting cells with these plasmids produces infectious virus, and by introducing deliberate mutations into any segment, scientists can figure out exactly which parts of each protein matter for attachment, replication, immune evasion, and everything else.34PubMed Central. Reverse Genetics Approaches for the Development of Influenza Vaccines
The same technology is central to vaccine production. Seasonal flu vaccines need to be updated constantly, and reverse genetics allows manufacturers to quickly swap in the HA and NA genes from newly circulating strains onto a well-characterized laboratory backbone that grows efficiently in eggs or cell culture. The approach works for both influenza A and influenza B: an eight-plasmid system for influenza B, for example, eliminated the need for older, slower methods that involved co-infecting cells with multiple viruses and selecting the right reassortant.35PubMed Central. Rescue of influenza B virus from eight plasmids More recent refinements allow researchers to assemble all eight segments in a single test-tube reaction before transfecting them into cells, streamlining the process further.36PLOS ONE. In vitro one-pot construction of influenza viral genomes for virus particle synthesis based on reverse genetics system Without reverse genetics, the detailed mechanistic picture of influenza described throughout this article — from cap-snatching to M2 channel function to NS1-mediated immune evasion — would be far less complete.